Company news
Brii Biosciences Limited (HKEX:2137) news
Brii Biosciences Limited news releases on 6ix. Latest, Aug 20, 2026: Brii Biosciences Provides Corporate Updates and Reports 2026 Interim Financial Results
Press releases & updates
Brii Biosciences Provides Corporate Updates and Reports 2026 Interim Financial Results
August 20, 2026
Brii Bio Announces Topline End-of-Treatment Data from Phase 2b ENRICH and ENHANCE Studies for the Treatment of Chronic Hepatitis B
July 2, 2026
Brii Bio Presents Late-Breaking Data from Its Phase 2 ENSURE Study at EASL Congress 2026, Further Supporting the Potential Role of BRII-179 in Achieving Durable Immunological Control of HBV
May 27, 2026
Brii Bio Presents Cross-Study Analysis of Post-Treatment HBsAg Rebound at APASL 2026
April 26, 2026
Brii Biosciences Provides Corporate Updates and Reports Full Year 2025 Financial Results
March 19, 2026
Brii Biosciences and OpenBench Announce AI-Driven Collaboration for Proprietary Technology Platform
December 11, 2025
Brii Biosciences Presents Late-Breaking Data from Ongoing Phase 2 ENSURE Study at AASLD 2025, Reinforcing BRII-179's Potential as a Curative Treatment for Chronic Hepatitis B
November 10, 2025
Brii Biosciences Announces Publication of Phase 2 ENSURE Study Results in Nature Medicine
November 7, 2025
Brii Biosciences Provides Corporate Updates and Reports 2025 Interim Financial Results
August 21, 2025
Brii Biosciences Announces Licensing Agreement with Joincare Group for Rights to BRII-693 in Greater China
July 2, 2025
Brii Bio Presents Late-Breaking Data from Its Ongoing Phase 2 ENSURE Study at EASL Congress 2025, Suggesting BRII-179's Role in Advancing Higher HBsAg Loss
May 7, 2025
Brii Bio Unveils New Data from Its Ongoing Phase 2 ENSURE Study at APASL 2025, Showcasing BRII-179's Unique Potential to Prime and Boost Higher HBsAg Loss Through Target Patient Identification
March 30, 2025
Brii Biosciences Provides Corporate Update and Reports Full-Year 2024 Financial Results
March 21, 2025
Brii Bio Announces Signing of Asset Purchase Agreements Acquiring BRII-179 IP Rights and Completed Patient Enrollment for ENRICH Study
January 2, 2025
Brii Bio Presents New Data from Its Ongoing Phase 2 Chronic Hepatitis B Trials at EASL™ Congress 2024
June 7, 2024
Brii Biosciences Announces Two Breakthrough Therapy Designations for BRII-877 and BRII-835 Building on Extensive Clinical Evidence from Multiple Phase 2 Studies
May 13, 2024
Brii Biosciences Announces Agreements To Acquire VBI Vaccines' IP Rights In BRII-179
March 5, 2024
Brii Biosciences Announces Agreement to Acquire VBI's IP Rights in BRII-179 (VBI-2601) and Plans to Initiate Technology Transfer to Expand Clinical and Commercial Supplies
February 12, 2024
Brii Biosciences Appoints Dr. Brian Alvin Johns as Chief Scientific Officer
January 3, 2024
Brii Biosciences Announces Topline Interim Results of Phase 2 Study Evaluating BRII-179 (VBI-2601) in Combination with PEG-IFNα for the Treatment of Chronic Hepatitis B
September 6, 2023
Brii Biosciences Provides Corporate Updates and Reports 2023 Interim Results
August 22, 2023
Brii Biosciences Broadens its Leadership in Hepatitis B with a Portfolio Now Addressing Disease's Burdens from Prevention to Cure
July 5, 2023
Brii Biosciences Provides Latest Clinical Development and Corporate Updates
July 5, 2023
Brii Biosciences Announces Entry into Definitive Agreements from Sale of its Equity Interest in Qpex Biopharma and Acquiring Exclusive Global Rights for BRII-693
June 25, 2023
Brii Biosciences Announces First Subject Dosed in Phase 1 Clinical Trial of BRII-297, Long-Acting Injectable for the Treatment of Anxiety and Depressive Disorders
May 30, 2023
Brii Bio Publishes 2022 Environmental, Social and Governance Report
April 26, 2023
Brii Biosciences Announces Top-line Results from Phase 1 Study of BRII-296, A Long-Acting Therapy in Development for Postpartum Depression
September 26, 2022